Trading Update

Fulcrum Pharma PLC
15 August 2007





Final                                                           15th August 2007

                               FULCRUM PHARMA PLC
                                ('the Company')


              Trading update and performance of Unicus acquisition

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services
company is pleased to give a year end trading update following the acquisition
of Unicus Regulatory Services Ltd ('Unicus'), a regulatory consultancy business,
in April 2007.

Group sales continue to grow, Japan has made a good contribution across the
business and the foreseen recovery of the US operation is underway. The results
for the Fulcrum Group, excluding Unicus, for the year ended 31 August 2007 are
expected to be in line with market expectations. Unicus sales, however, have
been below forecast in the four months since the company was acquired and this
will reduce the overall Group profit for the year. Fulcrum management have
focussed Unicus on sales growth and cost control in order to restore
profitability.

Under the terms of the agreement to acquire Unicus, Fulcrum protected itself
against any shortfall in performance in the year ended 31 March 2008. As a
result, the initial cash consideration paid for the business is expected to be
circa £200,000 lower at £2.3 million and the additional earnout consideration to
be £500,000 rather than the maximum of £2,300,000 envisaged at the time of
acquisition.

Strategically, Unicus is an important step towards Fulcrum's goal of being a
leading provider of regulatory services to the pharmaceutical industry.

Jon Court, Chief Executive of Fulcrum Pharma, said: 'Fulcrum continues to
perform in line with market expectations and deliver improving EBITDA figures.
Going forward we expect Unicus to contribute to further improved profitability
of the Group.'

For further information, please contact:

Fulcrum Pharma PLC
Jon Court, Chief Executive                     Tel: [phone]

Seymour Pierce
Jonathan Wright                                Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated
development team that provides strategic and operational leadership required to
ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having
successfully floated in March 2000.





                      This information is provided by RNS
            The company news service from the London Stock Exchange